Having a vascular surgeon as part of the transcatheter aortic valve implantation (TAVI) multidisciplinary team has a significant impact on decreasing the number of deaths caused by vascular complications, according to Marc van Sambeek, Catharina Hospital, Eindhoven, The Netherlands. Van Sambeek presented data supporting the participation of a vascular surgeon in the Heart Team at the VEITHsymposium (14–18 November 2012, New York, USA).
BUELACH, Switzerland, November 15, 2012—BIOTRONIK has announced the twelve-month results from the prospective, multicenter, single-arm 4EVER study, which demonstrates the efficacy and safety of BIOTRONIK s Pulsar self-expanding stent system in 120 superficial femoral artery (SFA) patients.
MINNEAPOLIS -- Nov. 13, 2012 -- Consistent with its commitment to clinical excellence, Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company s Valiant® Captivia® stent graft system for the endovascular repair of isolated lesions (excluding dissections) of the descending segment of the thoracic aorta. This expanded indication includes the treatment of transections, commonly known as blunt traumatic aortic injuries.
Cook Medical has received FDA approval for the first drug-eluting stent to treat peripheral artery disease in the U.S. The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding metal stent coated with the drug paclitaxel to help prevent recurring narrowing of the artery.
Elx, noviembre de 2012.- El Servicio de Cirugía Vascular del Hospital del Vinalopó ha realizado con éxito una nueva técnica a un paciente de 40 años de edad con hipertensión arterial que, a pesar de ser tratado con múltiples fármacos, continúa presentando cifras de tensión muy elevadas.
Cook Medical has received FDA approval for the first drug-eluting stent to treat peripheral artery disease in the U.S. The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding metal stent coated with the drug paclitaxel to help prevent recurring narrowing of the artery. Drug-eluting stents are currently approved for use in coronary arteries in heart attack patients. Boston Scientific, Abbott Laboratories and Medtronic lead the market, but Cook s is the first of its kind for peripheral arteries.
The US Food and Drug Administration (FDA) has given Avinger approval to market its Ocelot System for the treatment of chronic total occlusions in patients with peripheral arterial disease.
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery (PPA). The S.M.A.R.T.® Stent, which has been approved for peripheral indication in international markets since 1999, is now the first stent in the Unites States with both Iliac and SFA indications.
Cordis Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery (PPA). The S.M.A.R.T.® Stent, which has been approved for peripheral indication in international markets since 1999, is now the first stent in the Unites States with both Iliac and SFA indications.
Boston Scientific Corporation (Natick, MA) announced the beginning of the MAJESTIC clinical trial of the company’s Innova peripheral vascular drug-eluting stent (DES) system.
Jan Brunkwall, from the Department of Vascular Surgery, University Clinics, University of Cologne, Germany, presented one-year results of ADSORB (A prospective randomised trial in acute uncomplicated type B dissections), the first ever randomised trial on acute uncomplicated type B dissections. Brunkwall presented the results at the European Society of Vascular Surgery annual meeting (ESVS, Bologna, Italy, 19–21 September) and at the Thoracic Aortic Masterclass, in September in London, UK.
Two studies presented at the Transcatheter Cardiovascular Therapeutics congress (TCT, Miami, USA, 22–26 October) showed that revascularisation with a drug-eluting balloon is a promising technique for the treatment of in-stent restenosis in the superficial femoral artery.
A study found that a nitinol stent performed better than balloon angioplasty alone in treating blockages of the popliteal artery, which runs through the leg behind the knee. Results of the ETAP trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
Results from the ETAP trial, presented by Thomas Zeller, professor of Clinic Cardiology and Angiology and chief of the Department of Angiology at Universitäts-Herzzentrum Freiburg Bad Krozingen, Germany, at the TCT congress, have found that a nitinol stent performed better than balloon angioplasty alone in treating blockages in the popliteal artery.
Among nearly 45,000 men who were followed up for more than two decades, those with the risk factors of smoking, hypertension, high cholesterol, and type 2 diabetes had an associated greater risk of developing peripheral arterial disease (PAD), according to a study published in the 24–31 October issue of the Journal of the American Medical Association (JAMA).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos